These findings highlight the potential of PUR and OLC as structurally distinct, mutation‐targeted inhibitors of tau aggregation and propagation, providing a rationale for their further development as candidate therapeutics for frontotemporal dementia. Here, MAPT is linked to frontotemporal dementia.